메뉴 건너뛰기




Volumn 9, Issue 6, 2014, Pages

Discovery of novel GPVI receptor antagonists by structure-based repurposing

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CINANSERIN; COLLAGEN; GLYCOPROTEIN VI; LOSARTAN; CARDIOTONIC AGENT; FIBRINOGEN RECEPTOR; MOLECULAR LIBRARY; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN BINDING;

EID: 84903398922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101209     Document Type: Article
Times cited : (26)

References (51)
  • 1
    • 84898604731 scopus 로고    scopus 로고
    • BHF British Heart Foundation Health Promotion Research Group
    • BHF (2009-2010) BHF coronary heart disease statistics. British Heart Foundation Health Promotion Research Group.
    • (2009) BHF Coronary Heart Disease Statistics
  • 2
    • 84855353573 scopus 로고    scopus 로고
    • Heart disease and stroke statistics -2012 update: A report from the American Heart Association
    • Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Heart disease and stroke statistics -2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
    • (2012) Circulation , vol.125
    • Roger, V.L.1    Go, A.S.2    Lloyd-Jones, D.M.3    Benjamin, E.J.4    Berry, J.D.5
  • 3
    • 84872231296 scopus 로고    scopus 로고
    • Newer agents in antiplatelet therapy: A review
    • Yeung J, Holinstat M (2012) Newer agents in antiplatelet therapy: a review. J Blood Med 3: 33-42.
    • (2012) J Blood Med , vol.3 , pp. 33-42
    • Yeung, J.1    Holinstat, M.2
  • 4
    • 75949128633 scopus 로고    scopus 로고
    • Antiplatelet therapies for the treatment of cardiovascular disease
    • Michelson AD (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 9: 154-169.
    • (2010) Nat Rev Drug Discov , vol.9 , pp. 154-169
    • Michelson, A.D.1
  • 6
    • 4344668661 scopus 로고    scopus 로고
    • Drug repositioning: Identifying and developing new uses for existing drugs
    • Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683. (Pubitemid 39173508)
    • (2004) Nature Reviews Drug Discovery , vol.3 , Issue.8 , pp. 673-683
    • Ashburn, T.T.1    Thor, K.B.2
  • 7
    • 79955407302 scopus 로고    scopus 로고
    • Drug discovery and development focusing on existing medicines: Drug re-profiling strategy
    • Mizushima T (2011) Drug discovery and development focusing on existing medicines: drug re-profiling strategy. J Biochem 149: 499-505.
    • (2011) J Biochem , vol.149 , pp. 499-505
    • Mizushima, T.1
  • 8
    • 84903373857 scopus 로고    scopus 로고
    • NIH National Institutes of Health
    • NIH (2012) Rescuing and Repurposing Drugs. National Institutes of Health.
    • (2012) Rescuing and Repurposing Drugs
  • 9
    • 79955428497 scopus 로고    scopus 로고
    • The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics
    • Huang R, Southall N, Wang Y, Yasgar A, Shinn P, et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3: 80ps16.
    • (2011) Sci Transl Med , vol.3
    • Huang, R.1    Southall, N.2    Wang, Y.3    Yasgar, A.4    Shinn, P.5
  • 10
    • 84868556569 scopus 로고    scopus 로고
    • Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification
    • Ballester PJ, Mangold M, Howard NI, Robinson RL, Abell C, et al. (2012) Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification. J R Soc Interface.
    • (2012) J R Soc Interface
    • Ballester, P.J.1    Mangold, M.2    Howard, N.I.3    Robinson, R.L.4    Abell, C.5
  • 11
    • 77649204282 scopus 로고    scopus 로고
    • Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists
    • Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, et al. (2010) Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem 53: 1799-1809.
    • (2010) J Med Chem , vol.53 , pp. 1799-1809
    • Katritch, V.1    Jaakola, V.P.2    Lane, J.R.3    Lin, J.4    Ijzerman, A.P.5
  • 12
    • 11144323163 scopus 로고    scopus 로고
    • Virtual screening of chemical libraries
    • Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432: 862-865.
    • (2004) Nature , vol.432 , pp. 862-865
    • Shoichet, B.K.1
  • 13
    • 55749101354 scopus 로고    scopus 로고
    • Molecular mechanisms of thrombus formation in ischemic stroke: Novel insights and targets for treatment
    • Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112: 3555-3562.
    • (2008) Blood , vol.112 , pp. 3555-3562
    • Stoll, G.1    Kleinschnitz, C.2    Nieswandt, B.3
  • 14
    • 34247643257 scopus 로고    scopus 로고
    • Targeting platelets in acute experimental stroke: Impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding
    • DOI 10.1161/CIRCULATIONAHA.107.691279
    • Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, et al. (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 115: 2323-2330. (Pubitemid 46685900)
    • (2007) Circulation , vol.115 , Issue.17 , pp. 2323-2330
    • Kleinschnitz, C.1    Pozgajova, M.2    Pham, M.3    Bendszus, M.4    Nieswandt, B.5    Stoll, G.6
  • 15
    • 4444260266 scopus 로고    scopus 로고
    • Platelet adhesion signalling and the regulation of thrombus formation
    • Gibbins JM (2004) Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117: 3415-3425.
    • (2004) J Cell Sci , vol.117 , pp. 3415-3425
    • Gibbins, J.M.1
  • 16
    • 77953922179 scopus 로고    scopus 로고
    • Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood
    • Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, et al. (2010) Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood 115: 5069-5079.
    • (2010) Blood , vol.115 , pp. 5069-5079
    • Pugh, N.1    Simpson, A.M.2    Smethurst, P.A.3    De Groot, P.G.4    Raynal, N.5
  • 17
    • 85027958733 scopus 로고    scopus 로고
    • Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans
    • Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, et al. (2011) Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123: 1891-1899.
    • (2011) Circulation , vol.123 , pp. 1891-1899
    • Ungerer, M.1    Rosport, K.2    Bultmann, A.3    Piechatzek, R.4    Uhland, K.5
  • 18
    • 84880753729 scopus 로고    scopus 로고
    • The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke
    • Goebel S, Li Z, Vogelmann J, Holthoff HP, Degen H, et al. (2013) The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke. PLoS One 8: e66960.
    • (2013) PLoS One , vol.8
    • Goebel, S.1    Li, Z.2    Vogelmann, J.3    Holthoff, H.P.4    Degen, H.5
  • 19
    • 68149163242 scopus 로고    scopus 로고
    • Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro
    • Muzard J, Bouabdelli M, Zahid M, Ollivier V, Lacapere JJ, et al. (2009) Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro. Febs J 276: 4207-4222.
    • (2009) Febs J , vol.276 , pp. 4207-4222
    • Muzard, J.1    Bouabdelli, M.2    Zahid, M.3    Ollivier, V.4    Lacapere, J.J.5
  • 20
    • 84860803422 scopus 로고    scopus 로고
    • Pathologic shear triggers shedding of vascular receptors: A novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels
    • Al-Tamimi M, Tan CW, Qiao J, Pennings GJ, Javadzadegan A, et al. (2012) Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 119: 4311-4320.
    • (2012) Blood , vol.119 , pp. 4311-4320
    • Al-Tamimi, M.1    Tan, C.W.2    Qiao, J.3    Pennings, G.J.4    Javadzadegan, A.5
  • 21
    • 33746658013 scopus 로고    scopus 로고
    • Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI
    • DOI 10.1182/blood-2006-01-010215
    • Horii K, Kahn ML, Herr AB (2006) Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 108: 936-942. (Pubitemid 44154628)
    • (2006) Blood , vol.108 , Issue.3 , pp. 936-942
    • Horii, K.1    Kahn, M.L.2    Herr, A.B.3
  • 23
    • 79952262090 scopus 로고    scopus 로고
    • FRED pose prediction and virtual screening accuracy
    • McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51: 578-596.
    • (2011) J Chem Inf Model , vol.51 , pp. 578-596
    • McGann, M.1
  • 24
    • 0347296066 scopus 로고    scopus 로고
    • Assessing the performance of OMEGA with respect to retrieving bioactive conformations
    • DOI 10.1016/S1093-3263(02)00204-8, PII S1093326302002048
    • Bostrom J, Greenwood JR, Gottfries J (2003) Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model 21: 449-462. (Pubitemid 36120775)
    • (2003) Journal of Molecular Graphics and Modelling , vol.21 , Issue.5 , pp. 449-462
    • Bostrom, J.1    Greenwood, J.R.2    Gottfries, J.3
  • 25
    • 0021895138 scopus 로고
    • 2+ indicators with greatly improved fluorescence properties
    • Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. The Journal of biological chemistry 260: 3440-3450. (Pubitemid 15114340)
    • (1985) Journal of Biological Chemistry , vol.260 , Issue.6 , pp. 3440-3450
    • Grynkiewicz, G.1    Poenie, M.2    Tsien, R.Y.3
  • 26
    • 33644990632 scopus 로고    scopus 로고
    • Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen
    • O'Connor MN, Smethurst PA, Farndale RW, Ouwehand WH (2006) Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen. J Thromb Haemost 4: 869-873.
    • (2006) J Thromb Haemost , vol.4 , pp. 869-873
    • O'Connor, M.N.1    Smethurst, P.A.2    Farndale, R.W.3    Ouwehand, W.H.4
  • 28
    • 77949363102 scopus 로고    scopus 로고
    • Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI
    • Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, et al. (2010) Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem 53: 2087-2093.
    • (2010) J Med Chem , vol.53 , pp. 2087-2093
    • Ono, K.1    Ueda, H.2    Yoshizawa, Y.3    Akazawa, D.4    Tanimura, R.5
  • 31
    • 0030790042 scopus 로고    scopus 로고
    • Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain
    • DOI 10.1016/S0014-5793(97)00926-5, PII S0014579397009265
    • Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. Febs Letters 413: 255-259. (Pubitemid 27353279)
    • (1997) FEBS Letters , vol.413 , Issue.2 , pp. 255-259
    • Gibbins, J.M.1    Okuma, M.2    Farndale, R.3    Barnes, M.4    Watson, S.P.5
  • 33
    • 84865148939 scopus 로고    scopus 로고
    • Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan
    • Murad JP, Espinosa EV, Ting HJ, Khasawneh FT (2012) Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 17: 308-314.
    • (2012) J Cardiovasc Pharmacol Ther , vol.17 , pp. 308-314
    • Murad, J.P.1    Espinosa, E.V.2    Ting, H.J.3    Khasawneh, F.T.4
  • 35
    • 33745188660 scopus 로고    scopus 로고
    • Screening in a spirit haunted world
    • Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 11: 607-615.
    • (2006) Drug Discov Today , vol.11 , pp. 607-615
    • Shoichet, B.K.1
  • 36
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022- 2031.
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3    Brunner, H.R.4    Ekman, S.5
  • 39
    • 33645546989 scopus 로고    scopus 로고
    • Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients
    • Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, et al. (2006) Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95: 253-259.
    • (2006) Thromb Haemost , vol.95 , pp. 253-259
    • Lepantalo, A.1    Mikkelsson, J.2    Resendiz, J.C.3    Viiri, L.4    Backman, J.T.5
  • 40
    • 67649645191 scopus 로고    scopus 로고
    • Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    • Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, et al. (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30: 1744-1752.
    • (2009) Eur Heart J , vol.30 , pp. 1744-1752
    • Varenhorst, C.1    James, S.2    Erlinge, D.3    Brandt, J.T.4    Braun, O.O.5
  • 42
    • 1442290149 scopus 로고    scopus 로고
    • Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
    • Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, et al. (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. Faseb J 18: 397-399.
    • (2004) Faseb J , vol.18 , pp. 397-399
    • Massberg, S.1    Konrad, I.2    Bultmann, A.3    Schulz, C.4    Munch, G.5
  • 44
    • 54349125060 scopus 로고    scopus 로고
    • Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors
    • Yang Q, Chen L, He X, Gao Z, Shen X, et al. (2008) Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. Chemical & pharmaceutical bulletin 56: 1400-1405.
    • (2008) Chemical & Pharmaceutical Bulletin , vol.56 , pp. 1400-1405
    • Yang, Q.1    Chen, L.2    He, X.3    Gao, Z.4    Shen, X.5
  • 45
    • 70049118536 scopus 로고    scopus 로고
    • Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke
    • Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, et al. (2009) Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovascular diseases 28: 505-513.
    • (2009) Cerebrovascular Diseases , vol.28 , pp. 505-513
    • Bal Dit Sollier, C.1    Crassard, I.2    Simoneau, G.3    Bergmann, J.F.4    Bousser, M.G.5
  • 46
    • 79958770159 scopus 로고    scopus 로고
    • Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
    • Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, et al. (2011) Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377: 2013-2022.
    • (2011) Lancet , vol.377 , pp. 2013-2022
    • Bousser, M.G.1    Amarenco, P.2    Chamorro, A.3    Fisher, M.4    Ford, I.5
  • 47
    • 0037414069 scopus 로고    scopus 로고
    • 2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin
    • DOI 10.1016/S0735-1097(03)00048-2
    • Belhassen L, Pelle G, Dubois-Rande JL, Adnot S (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. Journal of the American College of Cardiology 41: 1198-1204. (Pubitemid 36384909)
    • (2003) Journal of the American College of Cardiology , vol.41 , Issue.7 , pp. 1198-1204
    • Belhassen, L.1    Pelle, G.2    Dubois-Rande, J.-L.3    Adnot, S.4
  • 49
    • 0037174372 scopus 로고    scopus 로고
    • Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy
    • Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, et al. (2002) Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Jama 288: 1491-1498.
    • (2002) Jama , vol.288 , pp. 1491-1498
    • Kjeldsen, S.E.1    Dahlof, B.2    Devereux, R.B.3    Julius, S.4    Aurup, P.5
  • 50
    • 71549127400 scopus 로고    scopus 로고
    • Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial
    • Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, et al. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374: 1840-1848.
    • (2009) Lancet , vol.374 , pp. 1840-1848
    • Konstam, M.A.1    Neaton, J.D.2    Dickstein, K.3    Drexler, H.4    Komajda, M.5
  • 51
    • 84860112460 scopus 로고    scopus 로고
    • The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: Current standing of the angiotensin hypothesis?
    • Kehoe PG, Passmore PA (2012) The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 30 Suppl 2: S251-268.
    • (2012) J Alzheimers Dis , vol.30 , Issue.SUPPL. 2
    • Kehoe, P.G.1    Passmore, P.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.